See more : Shanghai Zhezhong Group Co.,Ltd (002346.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of GRI Bio, Inc. (GRI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GRI Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Benson Hill, Inc. (BHIL) Income Statement Analysis – Financial Results
- Karsten S.A. (CTKA4.SA) Income Statement Analysis – Financial Results
- Titan Medical Inc. (TMDI) Income Statement Analysis – Financial Results
- PageGroup plc (MPGPY) Income Statement Analysis – Financial Results
- China Merchants Securities Co., Ltd. (600999.SS) Income Statement Analysis – Financial Results
GRI Bio, Inc. (GRI)
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 21.77M | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Cost of Revenue | 57.00K | 206.00K | 73.00K | 0.00 | 735.00 | 612.00 |
| Gross Profit | 21.71M | -206.00K | -73.00K | 100.00K | -735.00 | -612.00 |
| Gross Profit Ratio | 99.74% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.23M | 242.00K | 249.00K | 3.71M | 1.88M | 3.51M |
| General & Administrative | 1.49M | 2.00M | 813.00K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.10M | 2.00M | 813.00K | 1.11M | 1.27M | 800.08K |
| Other Expenses | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.33M | 2.24M | 1.06M | 4.81M | 3.15M | 4.31M |
| Cost & Expenses | 11.39M | 2.24M | 1.06M | 4.89M | 3.15M | 4.31M |
| Interest Income | 0.00 | 26.00K | 0.00 | 0.00 | 0.00 | 1.06K |
| Interest Expense | 2.08M | 653.00K | 547.00K | 34.00K | 197.03K | 0.00 |
| Depreciation & Amortization | 57.00K | 50.00K | 73.00K | 75.00K | 735.00 | 612.00 |
| EBITDA | -10.90M | -2.51M | -9.21M | -4.71M | -3.27M | -4.31M |
| EBITDA Ratio | -50.07% | 0.00% | 0.00% | -4,713.00% | 0.00% | 0.00% |
| Operating Income | -11.39M | -2.24M | -1.06M | -4.79M | -3.15M | -4.31M |
| Operating Income Ratio | -52.31% | 0.00% | 0.00% | -4,788.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -978.00K | -8.24M | -34.00K | -310.07K | 1.06K |
| Income Before Tax | -13.04M | -3.22M | -1.56M | -4.82M | -3.46M | -4.31M |
| Income Before Tax Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.77M | 325.00K | -50.00K | -131.30K | 5.00 | -2.00 |
| Net Income | -13.04M | -3.54M | -1.51M | -4.82M | -3.46M | -4.31M |
| Net Income Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| EPS | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| EPS Diluted | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| Weighted Avg Shares Out | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
| Weighted Avg Shares Out (Dil) | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and...
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?
LA JOLLA, CA / ACCESSWIRE / September 1, 2023 / Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is...
GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign
La Jolla, California--(Newsfile Corp. - August 29, 2023) - GRI Bio, Inc. (NASDAQ: GRI), a clinical-stage biotechnology company developing novel immunotherapies that modulate natural killer T (NKT) cells, today announced it has engaged B2i Digital, Inc. ("B2i") to execute an...
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus
LA JOLLA, CA / ACCESSWIRE / August 25, 2023 / Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that are...
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU
JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video Series
GRI Bio kicks-off the series by explaining what recently published preclinical data on its GRI-0803 Lupus development program means for its overall advancement FRENCHTOWN, NJ / ACCESSWIRE / August 16, 2023 / JTC Team ("JTC"), a fully integrated corporate communications...
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rapidly advancing c linical pipeline across multiple high-value i nflammatory, f ibrotic and a utoimmune d iseases
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
Data p resented at The Autoimmunity Conference h osted by the Federation of American Societies for Experimental Biology (FASEB)
JTC Team to Host Two Virtual Investor Spotlight Events on Thursday, July 27th
Live video webcasts with moderated interactive discussion with American Resources Corporation (NASDAQ:AREC) and GRI Bio (NASDAQ:GRI), respectively FRENCHTOWN, NJ / ACCESSWIRE / July 26, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27 th at 1:00 PM ET
Source: https://incomestatements.info
Category: Stock Reports